Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Andrology

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 26 articles: HTML format

Single Articles

April 2024
1. CAI X, Liang C, Zhang M, Dong Z, et al
   Mitochondrial DNA copy number and cancer risks: A comprehensive Mendelian randomization analysis.
   Int J Cancer. 2024;154:1504-1513.
   PubMed     Abstract available
   
   
   March 2024
2. DOHERTY N, Cardwell C, Murchie P, Hill C, et al
   Use of 5-alpha reductase inhibitors and risk of gastrointestinal cancers in men with benign prostatic hyperplasia: A population-based cohort study.
   Int J Cancer. 2024 Mar 30. doi: 10.1002/ijc.34937.
   PubMed     Abstract available
   
   
   February 2024
3. HAAVISTO A, Lampic C, Wettergren L, Lahteenmaki PM, et al
   Reproductive late effects and testosterone replacement therapy in male childhood cancer survivors: A population-based study (the Fex-Can study).
   Int J Cancer. 2024 Feb 22. doi: 10.1002/ijc.34890.
   PubMed     Abstract available
   
   
   December 2023
4. BREEKVELDT ECH, Ykema BLM, Bisseling TM, Moons LMG, et al
   Prevalence of neoplasia at colonoscopy among testicular cancer survivors treated with platinum-based chemotherapy.
   Int J Cancer. 2023 Dec 27. doi: 10.1002/ijc.34810.
   PubMed     Abstract available
   
   
   October 2023
5. HUGHES NF, Cromie KJ, Feltbower RG, McCabe MG, et al
   Delivered relative dose intensity in adolescent and young adult germ cell tumours in England: Assessment of data quality and consistency from clinical trials compared to national cancer registration data.
   Int J Cancer. 2023 Oct 20. doi: 10.1002/ijc.34762.
   PubMed     Abstract available
   
   
   August 2023
6. ALONSO-CRISOSTOMO L, Trendell J, Ferraresso M, Bailey S, et al
   Testicular germ cell tumour cells release microRNA-containing extracellular vesicles that induce phenotypic and genotypic changes in cells of the tumour microenvironment.
   Int J Cancer. 2023 Aug 26. doi: 10.1002/ijc.34697.
   PubMed     Abstract available
   
   
   June 2023
7. THORSEN L, Courneya KS, Steene-Johannessen J, Gran JM, et al
   Association of physical activity with overall mortality among long-term testicular cancer survivors: A longitudinal study.
   Int J Cancer. 2023 Jun 19. doi: 10.1002/ijc.34625.
   PubMed     Abstract available
   
   
   May 2023
8. HEMMINKI K, Forsti A, Liska V, Kanerva A, et al
   Long-term survival trends in solid cancers in the Nordic countries marking timing of improvements.
   Int J Cancer. 2023;152:1837-1846.
   PubMed     Abstract available
   
   
   June 2022
9. STARITA N, Pezzuto F, Sarno S, Losito NS, et al
   Mutations in the telomerase reverse transcriptase promoter and PIK3CA gene are common events in penile squamous cell carcinoma of Italian and Ugandan patients.
   Int J Cancer. 2022;150:1879-1888.
   PubMed     Abstract available
   
   
   May 2022
10. WATTS EL, Perez-Cornago A, Fensom GK, Smith-Byrne K, et al
    Circulating free testosterone and risk of aggressive prostate cancer: prospective and Mendelian randomization analyses in international consortia.
    Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34116.
    PubMed     Abstract available
    
    
    April 2022
11. XIU M, Zhang P, Wang X, Fan Y, et al
    Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant versus standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: a prospective cohort study with propensity-matched analysis.
    Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34022.
    PubMed     Abstract available
    
    
    March 2022
12. COUSIN S, Blay JY, Garcia IB, de Bono JS, et al
    Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
    Int J Cancer. 2022;150:993-1006.
    PubMed     Abstract available
    
    
    
13. ZNAOR A, Skakkebaek NE, Meyts ER, Kulis T, et al
    Global patterns in testicular cancer incidence and mortality in 2020.
    Int J Cancer. 2022 Mar 12. doi: 10.1002/ijc.33999.
    PubMed     Abstract available
    
    
    October 2021
14. SKOLD C, Koliadi A, Enblad G, Stalberg K, et al
    Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes.
    Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33844.
    PubMed     Abstract available
    
    
    
15. DICKEY BL, Fan W, Bettampadi D, Reich RR, et al
    Sequential acquisition of human papillomavirus infection between genital and oral anatomic sites in males.
    Int J Cancer. 2021;149:1483-1494.
    PubMed     Abstract available
    
    
    September 2021
16. LIU W, Liu Y, Hu C, Xu C, et al
    Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
    Int J Cancer. 2021;149:1369-1384.
    PubMed     Abstract available
    
    
    July 2021
17. LIU C, Huang B, Wu R, Chen J, et al
    Adequate asparaginase is important to prevent central nervous system and testicular relapse of pediatric Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.
    Int J Cancer. 2021;149:158-168.
    PubMed     Abstract available
    
    
    June 2021
18. PAVONE R, Pacquement H, Pasquet M, Sudour-Bonnange H, et al
    Childhood ovarian non-seminomatous germ cell tumors: A Highly Curable Disease With Few Long-Term Treatment-Related Toxicities. Results of the French TGM95 study.
    Int J Cancer. 2021 Jun 19. doi: 10.1002/ijc.33710.
    PubMed     Abstract available
    
    
    March 2021
19. WATTS EL, Perez-Cornago A, Knuppel A, Tsilidis KK, et al
    Prospective analyses of testosterone and SHBG with risk of 19 types of cancer in men and postmenopausal women in UK Biobank.
    Int J Cancer. 2021 Mar 15. doi: 10.1002/ijc.33555.
    PubMed     Abstract available
    
    
    
20. GU W, Wan F, Chen J, Gan H, et al
    Identification of a methylation panel aid in risk stratification in node-positive penile squamous cell carcinoma.
    Int J Cancer. 2021;148:1289-1298.
    PubMed     Abstract available
    
    
    February 2021
21. ARTHUR RS, Dannenberg AJ, Rohan TE
    The association of prediagnostic circulating levels of cardiometabolic markers, testosterone and SHBG with risk of breast cancer among normal weight postmenopausal women in the UK Biobank.
    Int J Cancer. 2021 Feb 10. doi: 10.1002/ijc.33508.
    PubMed     Abstract available
    
    
    December 2020
22. ROUTH JC, Dasgupta R, Chi YY, Shnorhavorian M, et al
    Impact of local control and surgical lymph node evaluation in localized paratesticular rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
    Int J Cancer. 2020;147:3168-3176.
    PubMed     Abstract available
    
    
    November 2020
23. WATTS EL, Fensom GK, Smith Byrne K, Perez-Cornago A, et al
    Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200,000 men in UK Biobank.
    Int J Cancer. 2020 Nov 30. doi: 10.1002/ijc.33416.
    PubMed     Abstract available
    
    
    May 2020
24. STANG A, Wellmann I, Kajuter H, Trocchi P, et al
    Differences in site-specific incidence and relative survival of cutaneous and mucocutaneous genital squamous cell carcinoma in Germany, 2007-2015.
    Int J Cancer. 2020 May 23. doi: 10.1002/ijc.33109.
    PubMed     Abstract available
    
    
    April 2020
25. JIANG YT, Gong TT, Zhang JY, Li XQ, et al
    Infertility and ovarian cancer risk: evidence from nine prospective cohort studies.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33012.
    PubMed     Abstract available
    
    
    
26. IDAHL A, Cornet CL, Maldonado SG, Waterboer T, et al
    Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort.
    Int J Cancer. 2020 Apr 3. doi: 10.1002/ijc.32999.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Andrology is free of charge.